Fresh from the biotech pipeline: fewer approvals, but biologics gain share

Fresh from the biotech pipeline: fewer approvals, but biologics gain share

2022 saw a 25% drop in new drug approvals and a less predictable regulator.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature biotechnology 2023-02, Vol.41 (2), p.174-182
1. Verfasser: Senior, Melanie
Format: Artikel
Sprache:eng
Schlagworte:
Agriculture
Bioinformatics
Biological Factors
Biological Products - therapeutic use
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Drug Approval
Life Sciences
News Feature
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 182
container_issue 2
container_start_page 174
container_title Nature biotechnology
container_volume 41
creator Senior, Melanie
description 2022 saw a 25% drop in new drug approvals and a less predictable regulator.
doi_str_mv 10.1038/s41587-022-01630-6
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9838261</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2763333532</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-bc5263ae442ee0a0e0bdec7053abe699dda67cf1dfbaca01c534f90a07ab3cb03</originalsourceid><addsrcrecordid>eNp9kUtP3DAUhS1EBRT4A11Ulrph0bR-5SbpAgmh0oeQuoG1ZTs3E6NMnNoJFf--ns50-ljgjS2d75zrq0PIK87ecSbr90nxsq4KJkTBOEhWwAE54aWCgkMDh_nNNjIv4Zi8TOmBMQYK4IgcSwCRzfKEfL2JmHraxbCmc4_U-jCj6-nkJxz8iB9ohz8wUjNNMTyaIb2ldpk32BBW3iW6Mn6kqTcRz8iLLgN4vrtPyf3Nx7vrz8Xtt09frq9uC6cqNRfWlQKkQaUEIjMMmW3RVayUxiI0TdsaqFzH284aZxh3pVRdk8HKWOksk6fkcps7LXaNrcNxjmbQU_RrE590MF7_q4y-16vwqJta1gJ4DrjYBcTwfcE067VPDofBjBiWpEUFMp9Sioy--Q99CEsc83qZqqBuuFCQKbGlXAwpRez2n-FMb6rS26p0rkr_qkpvTK__XmNv-d1NBuQWSFkaVxj_zH4m9idLOqCB</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2776891246</pqid></control><display><type>article</type><title>Fresh from the biotech pipeline: fewer approvals, but biologics gain share</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><creator>Senior, Melanie</creator><creatorcontrib>Senior, Melanie</creatorcontrib><description>2022 saw a 25% drop in new drug approvals and a less predictable regulator.</description><identifier>ISSN: 1087-0156</identifier><identifier>EISSN: 1546-1696</identifier><identifier>DOI: 10.1038/s41587-022-01630-6</identifier><identifier>PMID: 36624153</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>Agriculture ; Bioinformatics ; Biological Factors ; Biological Products - therapeutic use ; Biomedical and Life Sciences ; Biomedical Engineering/Biotechnology ; Biomedicine ; Biotechnology ; Drug Approval ; Life Sciences ; News Feature</subject><ispartof>Nature biotechnology, 2023-02, Vol.41 (2), p.174-182</ispartof><rights>The Author(s), under exclusive licence to Springer Nature America, Inc. 2023</rights><rights>Copyright Nature Publishing Group Feb 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-bc5263ae442ee0a0e0bdec7053abe699dda67cf1dfbaca01c534f90a07ab3cb03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41587-022-01630-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41587-022-01630-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36624153$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Senior, Melanie</creatorcontrib><title>Fresh from the biotech pipeline: fewer approvals, but biologics gain share</title><title>Nature biotechnology</title><addtitle>Nat Biotechnol</addtitle><addtitle>Nat Biotechnol</addtitle><description>2022 saw a 25% drop in new drug approvals and a less predictable regulator.</description><subject>Agriculture</subject><subject>Bioinformatics</subject><subject>Biological Factors</subject><subject>Biological Products - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering/Biotechnology</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Drug Approval</subject><subject>Life Sciences</subject><subject>News Feature</subject><issn>1087-0156</issn><issn>1546-1696</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kUtP3DAUhS1EBRT4A11Ulrph0bR-5SbpAgmh0oeQuoG1ZTs3E6NMnNoJFf--ns50-ljgjS2d75zrq0PIK87ecSbr90nxsq4KJkTBOEhWwAE54aWCgkMDh_nNNjIv4Zi8TOmBMQYK4IgcSwCRzfKEfL2JmHraxbCmc4_U-jCj6-nkJxz8iB9ohz8wUjNNMTyaIb2ldpk32BBW3iW6Mn6kqTcRz8iLLgN4vrtPyf3Nx7vrz8Xtt09frq9uC6cqNRfWlQKkQaUEIjMMmW3RVayUxiI0TdsaqFzH284aZxh3pVRdk8HKWOksk6fkcps7LXaNrcNxjmbQU_RrE590MF7_q4y-16vwqJta1gJ4DrjYBcTwfcE067VPDofBjBiWpEUFMp9Sioy--Q99CEsc83qZqqBuuFCQKbGlXAwpRez2n-FMb6rS26p0rkr_qkpvTK__XmNv-d1NBuQWSFkaVxj_zH4m9idLOqCB</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Senior, Melanie</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>M7S</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230201</creationdate><title>Fresh from the biotech pipeline: fewer approvals, but biologics gain share</title><author>Senior, Melanie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-bc5263ae442ee0a0e0bdec7053abe699dda67cf1dfbaca01c534f90a07ab3cb03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Agriculture</topic><topic>Bioinformatics</topic><topic>Biological Factors</topic><topic>Biological Products - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering/Biotechnology</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Drug Approval</topic><topic>Life Sciences</topic><topic>News Feature</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Senior, Melanie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection (ProQuest)</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nature biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Senior, Melanie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fresh from the biotech pipeline: fewer approvals, but biologics gain share</atitle><jtitle>Nature biotechnology</jtitle><stitle>Nat Biotechnol</stitle><addtitle>Nat Biotechnol</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>41</volume><issue>2</issue><spage>174</spage><epage>182</epage><pages>174-182</pages><issn>1087-0156</issn><eissn>1546-1696</eissn><abstract>2022 saw a 25% drop in new drug approvals and a less predictable regulator.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>36624153</pmid><doi>10.1038/s41587-022-01630-6</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1087-0156
ispartof Nature biotechnology, 2023-02, Vol.41 (2), p.174-182
issn 1087-0156
1546-1696
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9838261
source MEDLINE; Springer Nature - Complete Springer Journals; Nature Journals Online
subjects Agriculture
Bioinformatics
Biological Factors
Biological Products - therapeutic use
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Drug Approval
Life Sciences
News Feature
title Fresh from the biotech pipeline: fewer approvals, but biologics gain share
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T14%3A25%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fresh%20from%20the%20biotech%20pipeline:%20fewer%20approvals,%20but%20biologics%20gain%20share&rft.jtitle=Nature%20biotechnology&rft.au=Senior,%20Melanie&rft.date=2023-02-01&rft.volume=41&rft.issue=2&rft.spage=174&rft.epage=182&rft.pages=174-182&rft.issn=1087-0156&rft.eissn=1546-1696&rft_id=info:doi/10.1038/s41587-022-01630-6&rft_dat=%3Cproquest_pubme%3E2763333532%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2776891246&rft_id=info:pmid/36624153&rfr_iscdi=true